Clinical Trial Update: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab and relatlimab in chordoma patients has completed enrollment and study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chordoma
• Unresectable Chordoma

Drugs mentioned

• Relatlimab (relatlimab)
• nivolumab (nivolumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Chordoma, Locally Advanced Chordoma | Phase 2 | Status: COMPLETED